ENTRY       D12058                      Drug
NAME        Elranatamab (USAN);
            Elranatamab (genetical recombination) (JAN);
            Elranatamab-bcmm;
            Elrexfio (TN)
PRODUCT     ELREXFIO (Pfizer Laboratories Div Pfizer)
            ELREXFIO (U.S. Pharmaceuticals)
FORMULA     C6440H9958N1738O2010S49
EXACT_MASS  145369.6741
MOL_WEIGHT  145459.5981
SEQUENCE    (Heavy chain)
            EVQLVESGGG LVQPGGSLRL SCAASGFTFS DYYMTWVRQA PGKGLEWVAF IRNRARGYTS
            DHNPSVKGRF TISRDNAKNS LYLQMNSLRA EDTAVYYCAR DRPSYYVLDY WGQGTTVTVS
            SASTKGPSVF PLAPCSRSTS ESTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS
            SGLYSLSSVV TVPSSNFGTQ TYTCNVDHKP 	SNTKVDKTVE RKCRVRCPRC
            PAPPVAGPSV FLFPPKPKDT LMISRTPEVT CVVVAVSHED PEVQFNWYVD GVEVHNAKTK
            PREEQFNSTF RVVSVLTVVH QDWLNGKEYK CKVSNKGLPS SIEKTISKTK GQPREPQVYT
            LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPMLDS DGSFFLYSRL
            TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK
            (heavy chain)
            EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYPMSWVRQA PGKGLEWVSA IGGSGGSLPY
            ADIVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARYW PMDIWGQGTL VTVSSASTKG
            PSVFPLAPCS RSTSESTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL
            SSVVTVPSSN FGTQTYTCNV DHKPSNTKVD KTVERKCEVE CPECPAPPVA GPSVFLFPPK
            PKDTLMISRT PEVTCVVVAV SHEDPEVQFN WYVDGVEVHN AKTKPREEQF NSTFRVVSVL
            TVVHQDWLNG KEYKCKVSNK GLPSSIEKTI SKTKGQPREP QVYTLPPSRE EMTKNQVSLT
            CEVKGFYPSD IAVEWESNGQ PENNYKTTPP MLDSDGSFFL YSKLTVDKSR WQQGNVFSCS
            VMHEALHNHY TQKSLSLSPG K
            (Light chain)
            DIVMTQSPDS LAVSLGERAT INCKSSQSLF NVRSRKNYLA WYQQKPGQPP KLLISWASTR
            ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCKQSYDL FTFGSGTKLE IKRTVAAPSV
            FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
            SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
            (light chain)
            EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLMY DASIRATGIP
            DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYQSWPLTFG QGTKVEIKRT VAAPSVFIFP
            PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL
            TLSKADYEKH KVYACEVTHQ GLSSPVTKSF NRGEC
            (Disulfide bridge: H22-H98, H135-L219, H148-H204, H223-h217, H227-h221, H230-h224, H261-H321, H367-H425, h22-h96, h129-l215, h142-h198, h255-h315, h361-h419, L23-L94, L139-L199, l23-l89, l135-l195)
  TYPE      Peptide
REMARK      Product: D12058<US>
EFFICACY    Antineoplastic
  DISEASE   Multiple myeloma [DS:H00010]
  TYPE      Monoclonal antibody
TARGET      CD3E [HSA:916] [KO:K06451]
  PATHWAY   hsa04640(916)  Hematopoietic cell lineage
            hsa04660(916)  T cell receptor signaling pathway
BRITE       Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               CD molecules
                CD3E
                 D12058  Elranatamab (USAN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D12058
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D12058
DBLINKS     CAS: 2408850-14-4
///
